GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Recce Pharmaceuticals Ltd (ASX:RCE) » Definitions » Research & Development

Recce Pharmaceuticals (ASX:RCE) Research & Development : A$0.00 Mil (TTM As of Dec. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Recce Pharmaceuticals Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Recce Pharmaceuticals's Research & Development for the six months ended in Dec. 2024 was A$0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2024 was A$0.00 Mil.

Recce Pharmaceuticals Research & Development Historical Data

The historical data trend for Recce Pharmaceuticals's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Recce Pharmaceuticals Research & Development Chart

Recce Pharmaceuticals Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Research & Development
Get a 7-Day Free Trial Premium Member Only - - - - -

Recce Pharmaceuticals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Recce Pharmaceuticals Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Recce Pharmaceuticals  (ASX:RCE) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Recce Pharmaceuticals Research & Development Related Terms

Thank you for viewing the detailed overview of Recce Pharmaceuticals's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Recce Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Recce Pharmaceuticals Ltd (ASX:RCE) » Definitions » Research & Development
Comparable Companies
ASX:ATH ASX:ATX ASX:AGN ASX:IMU ASX:NUZ ASX:EZZ ASX:ACW ASX:LTP ASX:PAR ASX:RAD VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:UCB XBRU:ARGX ONC XKRX:068270 BNTX
Traded in Other Exchanges
RECEF:USA R9Q:Germany
Address
180 George Street, Level 23, Salesforce Tower, Sydney, NSW, AUS, 2000
Website
https://www.recce.com.au
Recce Pharmaceuticals Ltd is an Australia-based globally-focused biotechnology company engaged in the development and commercialization of a new class of antibiotics. The company operates in only one business segment being research and development of pharmaceutical drugs. The firm operates in three geographic segments being Australia, the United Kingdom, and the United States of America, of which the majority of the revenue comes from Australia. The company offers antibiotic drugs to treat diseases caused by various bacteria namely Sepsis, Neisseria gonorrhoeaei, Escherichia coli, Mycobacterium abscessus, and others.

Recce Pharmaceuticals Headlines

No Headlines